middle.news
Echo IQ wins FDA review route for EchoSolv HF after clearance setback
9:41am on Monday 12th of October, 2026 AEDT
•
Medical Technology
Read Story
Echo IQ wins FDA review route for EchoSolv HF after clearance setback
9:41am on Monday 12th of October, 2026 AEDT
Key Points
FDA accepts Echo IQ’s supervisory review request
EchoSolv HF remains subject to a Not Substantially Equivalent determination
FDA meeting expected within 30 days
Outcome and future regulatory pathway remain unresolved
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
EchoIQ (ASX:EIQ)
OPEN ARTICLE